Table 1 Major resistance pathways for currently available INSTIs
From: What if HIV were unable to develop resistance against a new therapeutic agent?
Raltegravir/Elvitegravir | Dolutegravir |
|---|---|
Y143 pathway | |
Y143C | |
Y143R | |
T97A/Y143C | |
T97A/Y143R | |
L74M/T97A/Y143G | |
L74M/T97A/E138A/Y143C | R263K |
N155H pathway | |
N155H | |
L74M/N155H | |
E92Q/N155H | |
E92Q pathway | |
E92Q | |
T66I/E92Q | |
E92Q/S153A | |
E92Q/H51Y/L768V | |
Q148 pathway | |
Q148H | |
Q148K | |
Q148R | |
E138K/Q148H | |
E138K/Q148K | |
E138K/Q148R | |
G140S/Q148H | |
G140S/Q148K | |
G140S/Q148R | |
E138A/G140S/Y143H/Q148H |